Bridgepoint Development Capital To Acquire Quotient Clinical
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.
Quotient's platform, which "offers an integrated approach to formulation development, 'real-time' drug product manufacturing and clinical testing," has been proven to reduce the time and cost of early stage drug development. A global company, Quotient has two primary facilities in the UK, and more that 3/4 of its revenues are from customers in the US or mainland Europe.
The financial details of the acquisition were undisclosed.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
